A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour
An Phase II Clinical Study on the Safety, Tolerability and Efficacy of HRS-7058 in Combination With Antitumor Drugs in Subjects With Solid Tumors
Shandong Suncadia Medicine Co., Ltd.
300 participants
Apr 28, 2025
INTERVENTIONAL
Conditions
Summary
This study is a multicentre, open phase II clinical study of dose escalation, dose extension and efficacy extension of HRS-7058 in combination with antitumor drugs in subjects with advanced malignant tumour. To evaluate the safety, tolerability and efficacy of HRS-7058 in combination with antitumor drugs.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
HRS-7058 + SHR-1316
HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapy
HRS-7058 + Cetuximab
HRS-7058 + SHR-1826
HRS-7058 + SHR-1826 + SHR-1316
HRS-7058 + SHR-A1202
HRS-7058 + BP102
HRS-7058 + SHR-9839
HRS-7058 +SHR-A2102 +SHR-1316
HRS-7058 +SHR-9839(sc)+SHR-1316
HRS-7058 +SHR-1316 +BP102
HRS-7058 +SHR-A2102 +BP102
HRS-7058 +SHR-A2102 +SHR-1316 +BP102
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06915142